The SIRFLOX study, with a primary endpoint of Progression Free Survival, is a prospective randomized study looking at SIR-Spheres microspheres in combination with chemotherapy for first line treatment of patients with unresectable liver metastases from colorectal cancer. WILMINGTON, Mass.–(EON: Enhanced Online News)–Sirtex, a leading developer of targeted and innovative liver cancer therapies, provided an update on clinical initiatives regarding SIR-Spheres microspheres. Dr. Batash offers comprehensive care for patients with Hepatitis C and other liver diseases in Queens, NY. Batash offers comprehensive care for patients with Hepatitis C and other liver diseases in NYC. The Food and Drug Administration (FDA) has approved Merit Medical Systems, phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres (hqTACE) for delivery of doxorubicin. The aim of SIRFLOX is to determine if SIR-Spheres microspheres in combination with FOLFOX6 with or without bevacizumab can be considered a valid first line option for patients with liver-limited metastatic colorectal cancer.
SIRFLOX is the first prospective randomized study looking at SIR-Spheres microspheres in combination with standard therapy for first line treatment, FOLFOX6 with or without bevacizumab, in patients with unresectable liver metastases from colorectal cancer. About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumors. Manufactured by Sirtex, SIR-Spheres microspheres are the only FDA-approved microsphere radiation therapy for the treatment of colorectal liver metastases. SIRT has been found to shrink liver tumors more than chemotherapy alone. The SIRFLOX study is open and enrolling at more than 40 sites worldwide. In addition to the two completed studies, Sirtex also released updates regarding a larger, independent global study currently enrolling patients at 40 sites including several in the United States. Information regarding other disease states or agents in combination with this device, that is presented in peer-reviewed literature or medical meetings may differ from the approved USA indications as per the labeling for the product.
- Increase bile secretion and improve digestion process inside liver
- 8 years ago from West Virginia
- Replace junk foods and beverages with fresh fruits, vegetables and whole grains in your diet
- 6 years ago from North Georgia
- It will help with better sugar control
- 8 years ago
Some people with this form of hepatitis never have symptoms, but those who do may experience joint pain, stomach pain, itchy skin, muscle soreness, dark urine, jaundice, or fatigue. Expert care from a GI specialist can address your medical needs whether you were recently infected and have acute hepatitis or you have a chronic hepatitis infection that has lasted over 6 months. Since Hepatitis C is caused by a virus, it is important to treat this condition to avoid permanent liver damage. The liver plays a critical role in fighting infection, cleaning your blood, and storing energy. We understand the unique challenges faced by patients with this form of liver disease and offer treatments that are easier and more comfortable than older methods that involved painful shots. Apricus Biosciences Inc. said Monday it reached an agreement with the Food and Drug Administration on the design of a trial for a potential liver cancer drug, making approval more likely if the study is successful.
Investigators noted that SIR-Spheres microspheres should be considered as a valid therapeutic option for patients with chemotherapy-refractory liver-limited metastatic colorectal cancer (mCRC). All patients in the control arm were reassessed for suitability for SIR-Spheres microspheres, with 43 percent of patients receiving Selective Internal Radiation Therapy (SIRT). For ethical reasons, the trial included a cross-over design for patients in the control arm following failure of chemotherapy alone. Median survival increased from 7.3 months in the chemotherapy control arm to 10 months in the SIR-Spheres microspheres plus chemotherapy arm. The median overall survival for the trial was 12.6 months. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity, and improved quality of life. Liver Cancer: Video Understanding SIR-Spheres microspheres – Whats Being Discussed ?